AI-generated summary
The authors reviewed studies of vaginal CO2 laser therapy for genitourinary syndrome of menopause in breast cancer survivors. Most observational studies reported within-group symptom improvement and good short-term tolerability, while the two sham-controlled randomized trials showed no clinically meaningful benefit over sham treatment. The authors state that evidence remains limited and more adequately powered trials are needed.
- Studies included
- 22
- Who or what was studied
- Breast cancer survivors with genitourinary syndrome of menopause
- Limits stated in the abstract
- The authors note heterogeneous study designs, populations, outcome measures and follow-up durations, and that the randomized trials were small and not adequately powered.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Sham, Visual analogue scale. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.